| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 12/05/2002 | US20020182666 Human aminoacyl-tRNA synthetase polypeptides useful for the regulation of angiogenesis |
| 12/05/2002 | US20020182665 Increased recovery of active proteins |
| 12/05/2002 | US20020182661 Substrate analogs for MurG, methods of making same and assays using same |
| 12/05/2002 | US20020182656 Methods for regulating vascularization using GEF containing NEK-like kinase (GNK) |
| 12/05/2002 | US20020182655 Method for identifying ligands for G protein-coupled receptors |
| 12/05/2002 | US20020182638 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 12/05/2002 | US20020182621 Methods and compositions using cap43 proteins and nucleic acids to diagnose and treat cancer and other disorders |
| 12/05/2002 | US20020182614 Expression analysis of inhibitor of differentiation nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer |
| 12/05/2002 | US20020182612 Diagnosing inflammatory defects in humans; obtain nucleotide sequence sample, incubate with probe associated with preferential allele, detect hybridization, hybridization indicates sensitivty to inflammatory defect |
| 12/05/2002 | US20020182582 Process for preparing agents containing virus-inactivated vitamin K-dependent plasma components as well as protein C and protein S by membrane chromatography |
| 12/05/2002 | US20020182269 Cucumis melo extract coated and/or microencapsulated in a fat-soluble agent based on a fatty substance |
| 12/05/2002 | US20020182268 Plant extracts, especially for breast cancer |
| 12/05/2002 | US20020182254 Biodegradable blend of polycaprolactone and crystallization modifier composed of a crystalline fatty acid or crystalline fatty acid ester of polyhydric alcohol for use in the controlled release of biologically active proteins |
| 12/05/2002 | US20020182242 Especially for enhancing the repair of damaged or diseased bone and cartilage tissues. |
| 12/05/2002 | US20020182220 Isolating a heat shock protein 70- peptide complex from the mammal from tumor cells or cells infected with a virus, bacteria or infectious agent; and administering the heat shock protein peptide complex |
| 12/05/2002 | US20020182218 Therapeutic anti-melanoma compounds |
| 12/05/2002 | US20020182216 Eliciting a T-cell mediated immune response in an animal, comprising administering to the animal an extract of an egg comprising transfer factor generated by said source animal |
| 12/05/2002 | US20020182215 Especially the amino acid sequence Ile-Phe-Ala-Gly-Asp-Lys-Phe-Trp-Arg, preferably flanked by cysteine residues at the amino and carboxy termini. |
| 12/05/2002 | US20020182211 Binds CD80 and/or CD86; an alanine at position +29 is substituted with tyrosine, leucine, tryptophan, or threonine, and a leucine at position +104 is substituted with a glutamic acid |
| 12/05/2002 | US20020182210 Treatment of central nervous system diseases by antibodies against glatiramer acetate |
| 12/05/2002 | US20020182208 Glycosylated antibody |
| 12/05/2002 | US20020182207 Contacting said target molecule with a catalyst capable of chemically modifying said target molecule; catalyzing the attachment of the label to the target substance |
| 12/05/2002 | US20020182206 Treating an inflammatory disease by administrating a therapeutically effective amount of a PRO301, PRO362 or PRO245 antagonist, or fragment thereof. |
| 12/05/2002 | US20020182205 Administering a therapeutically effective amount of an agonist of the non-proteolytically activated thrombin receptor to the site. |
| 12/05/2002 | US20020182204 Combination of a taxane and a cyclin-dependent kinase |
| 12/05/2002 | US20020182202 Administering a food grade agent for emulsifying fat such as lipase, detergents, lecithins, or bile salts |
| 12/05/2002 | US20020182201 Matrix stabilized enzyme crystals and methods of use |
| 12/05/2002 | US20020182200 Use in stem cell mobilization, neuronal protection, and regulating hematopoiesis; inhibiting destruction of hematopoietic progenitor cells resulting from chemotherapy |
| 12/05/2002 | US20020182198 Purified MANF polypeptide (mature astrocyte-derived neurotrophic factor) of given sequence |
| 12/05/2002 | US20020182195 Universally applicable blood plasma |
| 12/05/2002 | US20020182193 Method of in vitro preconditioning healthy donor's myoblasts before transplantation thereof in compatible patients suffering of myopathies like muscular dystrophy, for improving transplantation success |
| 12/05/2002 | US20020182192 Administering bone marrow cells to the mammal, such as allogeneic cells or autologous cells engineered to express dystrophin or other gene products |
| 12/05/2002 | US20020182189 Compositions and methods for the repair and construction of bone and other tissue |
| 12/05/2002 | US20020182187 Method of decreasing radiation or radio-mimetic chemotherapy for hematopoietic pluripotent cell engraftment |
| 12/05/2002 | US20020182185 Method for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor |
| 12/05/2002 | US20020182183 With a bioactive ingredient such as vitamin, nutrient or mineral; increases stability and bioactivity of the active ingredient |
| 12/05/2002 | US20020182182 Recombinant viral vector encoding a human very low density lipoprotein (VLDL) receptor, operatively linked to regulatory sequences directing expression in a hepatocyte; familial hypercholesterolemia or hyperlipidemia |
| 12/05/2002 | US20020182181 Generated from a bacteriophage; gene expression inhibition |
| 12/05/2002 | US20020182179 Administering a polyethylene glcyol(peg) conjugated (pegylated) interferon-alfa sufficient to lower detectable HIV-1-RNA |
| 12/05/2002 | US20020182178 Use of interleukin - 15 |
| 12/05/2002 | US20020182177 Methods and compositions for promoting the maturation of monocytes |
| 12/05/2002 | US20020182176 Methods and compositions for promoting the maturation of monocytes |
| 12/05/2002 | US20020182175 Administration of a reactive oxygen species (ROS) inhibitor or scavenger (a histmine or its salt, ester, prodrug and agonist) and at least one monocyte maturation promoting agent (a cytokine) |
| 12/05/2002 | US20020182174 Methods and compositions for promoting the maturation of monocytes |
| 12/05/2002 | US20020182162 Nitric oxide (NO) donor+cGMP-PDE5 inhibitor as a topical drug for enhanced hair growth |
| 12/05/2002 | US20020182147 Vitronectin receptor antagonist pharmaceuticals |
| 12/05/2002 | DE10126970A1 Medicament or nutritional supplement containing phytic acid cleaving reagent, preferably phytase, useful for increasing bioavailability of bioelements, e.g. calcium and iron, and combating deficiency diseases |
| 12/05/2002 | CA2665748A1 Immunogenic peptide composition for the prevention and treatment of alzheimer's disease |
| 12/05/2002 | CA2487014A1 A method of improving the growth performance of an animal |
| 12/05/2002 | CA2483254A1 Tumor therapy |
| 12/05/2002 | CA2452707A1 Treatment or replacement therapy using transgenic stem cells delivered to the gut |
| 12/05/2002 | CA2449168A1 Iap binding peptides and assays for identifying compounds that bind iap |
| 12/05/2002 | CA2449160A1 Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method |
| 12/05/2002 | CA2449127A1 Recombinant dna encoding the major allergen of plantago lanceolata pollen pla l 1, and applications thereof |
| 12/05/2002 | CA2449004A1 Melanin-concentrating hormone analogs |
| 12/05/2002 | CA2449000A1 Bcl-2-modifying factor (bmf) sequences and their use in modulating apoptosis |
| 12/05/2002 | CA2448963A1 Pharmaceutical use for secreted bacterial effector proteins |
| 12/05/2002 | CA2448891A1 Long lasting fusion peptide inhibitors for hiv infection |
| 12/05/2002 | CA2448637A1 A pharmaceutical combination comprising either (s)-2-ethoxy-3 [4-(2- {4-methane sulfonyl oxyphenyl} ethoxy)phenyl] propanoic acid or 3-{4-[2- (4-tert-butoxy carbonylamino phenyl) ethoxy] phenyl}-(s)-2-ethoxy propanoic acid and insulin |
| 12/05/2002 | CA2448567A1 Modulators of nucleic acid ligands |
| 12/05/2002 | CA2448362A1 B7 related protein-2 molecules and uses thereof |
| 12/05/2002 | CA2448348A1 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
| 12/05/2002 | CA2448320A1 Ribozyme based treatment of female reproductive diseases |
| 12/05/2002 | CA2448171A1 Immunogenic peptide composition for the prevention and treatment of alzheimer's disease |
| 12/05/2002 | CA2448148A1 Carbohydrate-associated proteins |
| 12/05/2002 | CA2448146A1 Secreted proteins |
| 12/05/2002 | CA2448116A1 Molecules for disease detection and treatment |
| 12/05/2002 | CA2448109A1 Alternative splice forms of proteins as basis for multiple therapeutic modalities |
| 12/05/2002 | CA2448104A1 Wnv core protein/capsid interacting protein and uses of the same |
| 12/05/2002 | CA2448100A1 Chimeric proteins for cell targeting and apoptosis induction and methods of using the same |
| 12/05/2002 | CA2448096A1 Plant artificial chromosomes, uses thereof and methods of preparing plant artificial chromosomes |
| 12/05/2002 | CA2448062A1 Single amino acid based compounds for counteracting effects of reactive oxygen species and free radicals |
| 12/05/2002 | CA2447986A1 High affinity ligand for p75 neurotrophin receptor |
| 12/05/2002 | CA2447916A1 Tumor endothelial marker 7.alpha. molecules and uses thereof |
| 12/05/2002 | CA2447879A1 Attractin/mahogany-like polypeptides, polynucleotides, antibodies and methods of use thereof |
| 12/05/2002 | CA2447662A1 Transporters and ion channels |
| 12/05/2002 | CA2447648A1 Pharmaceutical combinations |
| 12/05/2002 | CA2447629A1 The lectin-like domain of thrombomodulin and its therapeutic use |
| 12/05/2002 | CA2446282A1 2-{[n-(2-amino-3-(heteroaryl or aryl)propionyl)-aminoacyl]-amino}-alkylboronic acid derivatives |
| 12/05/2002 | CA2443713A1 Proteins associated with cell growth, differentiation, and death |
| 12/05/2002 | CA2432187A1 Daptomycin and related analogs in crystalline form |
| 12/05/2002 | CA2411907A1 Preparation with vascular protective and anti-oxidative effect and use thereof |
| 12/04/2002 | EP1262556A2 Antimicrobial peptides and method for identifying and using such peptides |
| 12/04/2002 | EP1262548A1 Polypeptide inducing apoptosis |
| 12/04/2002 | EP1262546A1 Novel scavenger receptors |
| 12/04/2002 | EP1262490A1 GPib-LIPID BOND CONSTRUCT AND USE THEREOF |
| 12/04/2002 | EP1262489A1 Complex comprising recombinant ferritin and a precious metal and DNA encoding said ferritin |
| 12/04/2002 | EP1262488A2 Human LCCL-domain containing protein |
| 12/04/2002 | EP1262487A1 Dna encoding squalene epoxidase promoter |
| 12/04/2002 | EP1262200A2 Inhibition of platelet adherence and aggregation |
| 12/04/2002 | EP1262199A1 Vectors for enhanced expression of VEGF for disease treatment |
| 12/04/2002 | EP1262193A1 Use of human anti-CTLA-4 antibodies for treatment of cancer |
| 12/04/2002 | EP1262190A1 Rfrp-containing prolactin secretion regulatory agent |
| 12/04/2002 | EP1262189A1 Leptin-resistance ameliorating agents |
| 12/04/2002 | EP1262188A1 Improved neuronal gene transfer |
| 12/04/2002 | EP1262187A1 Use of hepcidin for preparing a medicament for treating disorders of iron homeostasis |
| 12/04/2002 | EP1262175A2 Use of renin-angiotensin antagonist for reducing post myocardial infarct mobidity and mortality |
| 12/04/2002 | EP1262169A2 Skin anti-ageing composition |
| 12/04/2002 | EP1262065A1 Method and system for providing a customized media list |
| 12/04/2002 | EP1261855A1 Gas sensor |